Regeneron (REGN) Tops Q2 EPS by $1.17
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Regeneron Reports Second Quarter 2022 Financial and Operating Results
August 3, 2022 6:30 AM EDTSecond quarter 2022 revenues decreased 44% to $2.86 billion versus second quarter 2021; excluding REGEN-COV®(a)(b), revenues increased 20%Second quarter 2022 EYLEA® U.S. net sales increased 14% versus second quarter 2021 to a record $1.62 billionSecond quarter 2022 Dupixent® global net sales(c)(recorded by Sanofi) increased 40% to $2.09 billion versus second quarter 2021Second quarter 2022 GAAP diluted EPS of $7.47; non-GAAP diluted EPS(a) of $9.77 including unfavorable $1.71 impact from acquired IPR&D chargesFDA approved Dupixent for atopic dermatitis in children aged 6 months to 5 years and eosinophilic esophagitis in adults and adolescents; FDA priority review granted for prurigo... More
